| Eugenio A Peluso, PHD | |
|
701 White Pond Dr, Suite 300, Akron, OH 44320-1155 | |
| (330) 572-1011 | |
| (330) 572-1018 |
| Full Name | Eugenio A Peluso |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 19 Years |
| Location | 701 White Pond Dr, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467657908 | NPI | - | NPPES |
| 3007570 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 6556 (Ohio) | Secondary |
| 103G00000X | Clinical Neuropsychologist | 6556 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unity Health Network Llc | 0244379717 | 78 |
News Archive
As the court begins its new term, the justices will be asked to consider another challenge to the Affordable Care Act about whether individuals can qualify for federal subsidies if they live in a state with a federal, rather than a state-run, insurance marketplace.
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration, which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.
› Verified 6 days ago
| Entity Name | Unity Health Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205169836 PECOS PAC ID: 0244379717 Enrollment ID: O20091124000005 |
News Archive
As the court begins its new term, the justices will be asked to consider another challenge to the Affordable Care Act about whether individuals can qualify for federal subsidies if they live in a state with a federal, rather than a state-run, insurance marketplace.
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration, which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eugenio A Peluso, PHD 701 White Pond Dr, Suite 300, Akron, OH 44320-1155 Ph: (330) 572-1011 | Eugenio A Peluso, PHD 701 White Pond Dr, Suite 300, Akron, OH 44320-1155 Ph: (330) 572-1011 |
News Archive
As the court begins its new term, the justices will be asked to consider another challenge to the Affordable Care Act about whether individuals can qualify for federal subsidies if they live in a state with a federal, rather than a state-run, insurance marketplace.
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration, which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.
› Verified 6 days ago